EOS imaging Appoints Chief Medical Officer

Expands Management Team to Support Continued Adoption of the EOS imaging System

Regulatory News:

EOS imaging (Paris:EOSI) (Euronext, FR0011191766 - EOSI), the pioneer in 2D/3D orthopedic medical imaging, today announced the appointment of Fabienne Hirigoyenberry-Lanson, Ph.D., as the Company's first Chief Medical Officer.

Dr. Hirigoyenberry-Lanson has 22 years of extensive experience of the medical device industry. Prior to joining EOS imaging, she was Vice President of Global Medical Affairs at Accuray Inc., a radiation oncology company, where she led clinical and key opinion leader programs to support and sustain market growth. Prior to Accuray, Dr. Hirigoyenberry-Lanson held several positions in medical device companies and major clinical research organizations. She attended the University of Science of Bordeaux (France) and received her Ph.D. in Biology in 1991.

Dr. Hirigoyenberry-Lanson commented, "EOS has developed a compelling new 2D/3D imaging option for orthopaedic treatment, which provides significant benefits to patients, physicians, hospitals and payors by helping to improve diagnosis and outcomes for orthopaedic patients. I look forward to further expanding the Company's clinical and medical affairs to support increased adoption of the EOS system."

Marie Meynadier, CEO of EOS imaging, said, "We are pleased to welcome Dr. Hirigoyenberry-Lanson to the EOS team. She has a proven track record in the medical device industry, including relevant experience with capital equipment and software driven systems. Her leadership will further enhance our clinical and medical affairs programs as we work to increase awareness and adoption of our unique low-dose, full-body 2D/3D imaging technology for orthopaedics."

For further information about the Company or EOS®, the first full-body, low dose 2D/3D imaging system, please visit www.eos-imaging.com.

About EOS imaging:
EOS imaging designs, develops, and markets EOS®, a revolutionary and patented medical imaging system, based on technology that enabled George Charpak to win the Nobel Prize for Physics. The Company is authorized to market the system in 31 countries, including the United States (FDA), Japan, Canada, Australia and the European Union (EU). Backed by an installed base of 75 sites and more than 400,000 imaging sessions, EOS® benefits from worldwide recognition within the global medical community. As of December 31, 2012 the Group posted 2012 consolidated revenue of ?9.42 million and employs 70 people including an R&D team of 25 engineers. The Group is based in Paris and holds three subsidiaries in Cambridge (Massachusetts), in Canada at Montreal and in Germany, and offices in Singapore. For further information, please visit www.eos-imaging.com

EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 - Ticker: EOSI

Next press release: Annual results 2013 on January 22, 2014 (after market).

EOS imaging
Anne Renevot
CFO
Ph: [phone]
[e-mail]
or
NewCap.
Financial communication and investor relations
Sophie Boulila / Pierre Laurent
Ph: [phone]
[e-mail]
or
The Ruth Group (US)
Press relations / Melanie Sollid-Penton
Ph: 646-536-7023
[e-mail]